Jeff Tornheim, MD, MPH

Role: 
Faculty
Assistant Professor
Jeff Tornheim, MD, MPH
Jeff Tornheim, MD, MPH, is Assistant Professor in the Division of Infectious Diseases here at Johns Hopkins University School of Medicine. His research explores the application of new diagnostic technologies to improved health outcomes in the treatment of drug resistant tuberculosis among both adult and pediatric patients in India. 

Dr. Tornheim recently completed his infectious diseases fellowship at Johns Hopkins, during which he worked with Drs. Amita Gupta, Vidya Mave, Bob Bollinger of Johns Hopkins, and with Dr. Zarir Udwadia at the Hinduja Hospital in Mumbai. His interest in clinical outcomes for underserved populations led him to practice in physician training environments in Bolivia, Peru, South Sudan, Kenya, Uganda, Rwanda, South Africa, and the United States.

Dr. Tornheim completed a clinical fellowship in infectious diseases in June 2017. Prior to that he completed residencies at Yale University in both internal medicine and pediatrics. He received an MD/MPH from Mount Sinai School of Medicine, with his thesis evaluating the impact of water policy on rates of pediatric diarrhea in Bolivia. After completing undergraduate studies in International Development and Economics at Brandeis University he moved to East Africa where he engaged in health system strengthening for returning refugees to South Sudan and worked with the Centers for Disease Control and Prevention (CDC) on the epidemiology of pneumonia and diarrhea in Western Kenya. At the same time he worked at the Bureau of TB Control for the Department of Health and Mental Hygiene and was actively engaged in the operations of an East Harlem free clinic. As a Fogarty International Clinical Scholar, he spent 2 years in rural Bolivia establishing and managing operations for a Chagas Disease treatment program.

 

Assessing Tuberculosis Transmission Dynamics, Drug Resistance and Recurrence Using Whole Genome Sequencing in Pune, India

Post Date: 
2018-06-12
   |   
Countries: 
Indo-JHU researchers are using combined geospatial and genotyping methods to describe TB transmission dynamics in a hyperlocal region of Pune City in Western India.

Predictors of Resistance Emergence Evaluation in Multidrug Resistant-Tuberculosis Patients on Treatment (PREEMPT Pilot Study)

Post Date: 
2018-03-20
   |   
Clinical Sites: 
   |   
Countries: 
Indo-JHU Clinical Resarch Partnership is participating with Brazilian colleagues in a 3-year effort led by Boston University to identify what contributes to TB drug resistance.

MDR-TB Free: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy

Post Date: 
2017-03-24
   |   
Clinical Sites: 
   |   
Countries: 
This study is also known as MDR-TB MUKT: M onitoring Adverse Effects, U tilizing Resources Optimally, K nowing Resistance Patterns, and T reatment Strategy. Purpose: To establish an observational cohort of MDR-TB cases and household contacts with accompanying biorepository at PD Hinduja National...

Multicenter Study of the Accuracy of the BD MAX MDR-TB Assay for Detection of M. tuberculosis Complex and Mutations Associated with Resistance to Rifampin or Isoniazid

Post Date: 
2017-03-01
   |   
Clinical Sites: 
   |   
Countries: 
In a multi-country study, we are assessing the accuracy of the BD MAX rapid MDR-TB assay to detect rifampin and isoniazid resistance.

RePORT: C-TRIUMPH: Substudy on Transcriptomic and Metabolomic Analysis of Microbiologically Confirmed Pediatric Tuberculosis Patients and Uninfected Household Contacts

Post Date: 
2016-09-01
   |   
Clinical Sites: 
   |   
Countries: 
The objectives for this study are to: Assess the RNAseq, microRNA, and metabolic signature differences between confirmed pediatric TB patients and age- and sex-matched controls who are all household contacts of known cases but have remained TST and IGRA negative. Determine which of the published...

Whole Genome Sequencing and Trek Sensititre Testing of Stored Isolates of Drug-resistant Tuberculosis from a Clinical Cohort at Hinduja Hospital, Mumbai

Post Date: 
2016-05-02
   |   
Clinical Sites: 
   |   
Countries: 
Among HIV-positive TB patients presenting to Médecins San Frontières (MSF) clinics in Mumbai, 78% carried MDR-TB strains, with nearly half also found to have additional drug resistance. A previously published cohort of 202 patients cared for at these MSF clinics have enrolled in a cross-sectional...

Whole Genome Sequencing of Clinical Isolates from Patients with Multidrug Resistant Tuberculosis in India 

Post Date: 
2015-11-12
   |   
Clinical Sites: 
   |   
Countries: 
Comparative genomic analysis using whole genome sequencing (WGS) offers an opportunity to understand the specific mutations associated with drug resistance and the phenotypic behavior of TB. As treatment programs incorporate more molecular diagnostics such as Xpert MTB/RIF and line probe assays, it...

BWI CTU: Baltimore-Washington-India Clinical Trials Unit

Post Date: 
2007-02-02
   |   
Clinical Sites: 
   |   
Countries: 
Comprising clinical trial sites at Johns Hopkins Medicine in Baltimore, Whitman Walker Health in Washington, DC, and the BJGMC-CCGHE collaboration in Pune, India, the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU) is one of only 25 international HIV/TB clinical trial sites funded by the...

Pyrosequencing to resolve discrepant Xpert MTB/RIF and Mycobacterial Growth Indicator Tube 960

Post Date: 
2018-03-26
   |   
Clinical Sites: 
   |   
Countries: 
Publication: 
Lung India
Lung India: Indo-JHU researchers find that pyrosequencing can clear up discrepancies about drug resistance in TB.

Of testing and treatment: Implications of implementing new regimens for multidrug-resistant tuberculosis

Post Date: 
2017-10-01
Publication: 
Clinical Infectious Diseases
A novel, shorter-course regimen for treating multidrug-resistant (MDR) tuberculosis was recently recommended by the World Health Organization. However, the most appropriate use of drug susceptibility testing (DST) to support this regimen is less clear. Implementing countries must therefore often...

Drug-resistant tuberculosis in 2017: at a crossroads

Post Date: 
2017-03-15
Publication: 
Lancet Respiratory Medicine
In The Lancet Respiratory Medicine, Dheda and colleagues present one of the most comprehensive pictures to date of the global epidemic of drug-resistant tuberculosis. This comes at a time of increasing awareness of antimicrobial resistance as a global threat, and Mycobacterium tuberculosis has had...

Tuberculosis associated with HIV infection

Post Date: 
2017-01-15
Publication: 
Microbiology Spectrum
Abstract Tuberculosis (TB) has recently surpassed HIV as the primary infectious disease killer worldwide, but the two diseases continue to display lethal synergy. The burden of TB is disproportionately borne by people living with HIV, particularly where HIV and poverty coexist. The impact of these...

Bedaquiline

Post Date: 
2017-01-01
Publication: 
Kucers’ the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, and Antiviral Drugs, 7th Edition
Section II, Antibiotics: Part 12 Anti-tuberculosis drugs.

Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system

Post Date: 
2016-06-13
Publication: 
Neurology, Neuroimmunology and Neuroinflammation
OBJECTIVE: To determine the feasibility of next-generation sequencing (NGS) microbiome approaches in the diagnosis of infectious disorders in brain or spinal cord biopsies in patients with suspected CNS infections. METHODS: In a prospective pilot study, we applied NGS in combination with a new...

Linezolid Experience Among MDR-TB Patients in Mumbai

Post Date: 
2018-03-16
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Baltimore, MD
Event & Convener: 
2018 Research Retreat, Johns Hopkins Department of Medicine
Abstract Presentation. Tornheim J.

Linezolid Experience Among MDR-TB Patients in Mumbai

Post Date: 
2018-02-15
   |   
Countries: 
Presentation Location: 
New Delhi, India
Event & Convener: 
RePORT India Annual Meeting
Oral Presentation. Tornheim JA, Ganatra S, Deluca A, Banka R, Rodrigues C, Gupta A, Udwadia ZF.

Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole Genome Sequencing to Identify Genes of Interest in Pune, India

Post Date: 
2018-02-15
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
New Delhi, India
Event & Convener: 
RePORT India Annual Meeting
Oral Presentation. Tornheim JA, Madugundu AK, Pradhan N, Bharadwaj R, Mave V, Golub J, Pandey A, Gupta A.

Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole Genome Sequencing to Identify Genes of Interest in Pune, India

Post Date: 
2017-10-12
   |   
Clinical Sites: 
Presentation Location: 
Guadalajara, Mexico
Event & Convener: 
48th Annual Union World Conference of Lung Health
Poster Presentation. Tornheim JA , Madugundu AK, Pradhan N, Bharadwaj R, Mave V, Golub J, Pandey A, Gupta A

Linezolid Experience among MDRTB Patients in Mumbai

Post Date: 
2017-09-13
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Milan, Italy
Event & Convener: 
ERS International Congress. European Respiratory Society
Tornheim J, Ganatra S, Deluca A, Banka R, Rodrigues C, Gupta A, Udwadia Z. Poster Presentation.

Gene Expression Profiles of Pediatric Tuberculosis Patients and Exposed Controls from India

Post Date: 
2017-09-13
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Rio de Janiero, Brazil
Event & Convener: 
RePORT International Conference. RICC
Poster Presentation. Tornheim JA , Paradkar M, Madugundu A, Gupte N, Kulkarni V, Sreenivasamurthy S, Raja R, Pradhan N, Shivakumar SVBY, Valvi C, Kohli R, Chandrasekaran P, Mave V, Pandey A, Gupta A.

CTRIUMPh Pediatric Biomarker Substudy

Post Date: 
2017-05-30
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Washington, DC
Event & Convener: 
2017 IMPAACT Annual Meeting
Tornheim J . Paradkar M. Invited presenter. Session: The Future of MDR-TB Treatment in Children.

It Simply Won’t Work Here – Few Eligible for the Newly Recommended Short Course MDR-TB Regimen in a Mumbai Private Clinic

Post Date: 
2017-05-21
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Washington, DC
Event & Convener: 
American Thoracic Society 2017 International Conference
Poster Presentation. Tornheim J , DeLuca A, Ganatra S, Radhika B, Gupta A, Udwadia Z.

Communicating Whole Genome Sequencing Results for Tuberculosis: What Does It Mean and Who Needs to Know?

Post Date: 
2017-04-25
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Mumbai, India
Event & Convener: 
Foundation for Medical Research
Invited lecture.

What are We Trying to Say Here? Standardizing Next Generation Sequencing Reports for Tuberculosis

Post Date: 
2017-03-30
Presentation Location: 
Washington, DC
Event & Convener: 
2017 Critical Path to TB Drug Regimens Annual Workshop.
Invited speaker

Impact of Drug Susceptibility Testing on Drug Choice in a Tuberculosis Cohort with High Rates of Drug Resistance from the Private Sector in Mumbai

Post Date: 
2017-02-03
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Hyderabad, India
Event & Convener: 
6th Annual Regional Prospective Observational Research for Tuberculosis (RePORT) India Joint Leadership Meeting
Poster presentation. Tornheim JA , Ganatra S, DeLuca A, Banka R, Gupta A, Udwadia ZF

Descriptive Baseline Characteristics, Treatment Outcomes and Biorepository of Pediatric TB Cases in CTRIUMPh-RePORT India Prospective Cohort

Post Date: 
2017-02-03
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
Hyderabad, India
Event & Convener: 
6th Annual Regional Prospective Observational Research for Tuberculosis (RePORT) India Joint Leadership Meeting
Poster presentation. Paradkar M , Kavitha D, Shiva Kumar SVBY, Khadse S, Khwaja S, Hari K, Rani N, Thiruvengadam K, Gupte N, Raskar S, Jain D, Suryavanshi S, Kohli R, Kulkarni V, Pradhan N, Sathyamurthi B, Tornheim J, Gupte A, DeLuca A, Mave V, Chandrasekaran P, Gupta A for the CTRIUMPH Study Team

Impact of Drug Susceptibility Testing on Drug Choice in a Tuberculosis Cohort with High Rates of Drug Resistance from the Private Sector in Mumbai

Post Date: 
2016-10-27
   |   
Clinical Sites: 
   |   
Countries: 
Presentation Location: 
New Orleans, LA
Event & Convener: 
ID Week 2016
Poster Abstract Session: Tuberculosis Treatment and Outcome. Udwadia ZF, Tornheim JA , Ganatra S, DeLuca A, Banka R, Gupta A

Tornheim Receives W. Leigh Thompson Excellence in Research Award

Post Date: 
2018-03-21
Dr. Jeffrey Tornheim
Jeff Tornheim's research on drug-resistant tuberculosis in India garners high honors from Johns Hopkins Department of Medicine.

Tornheim Promoted to Assistant Professor

Post Date: 
2017-08-31
His research explores whether 2 MDR-TB drug susceptibility tests using WGS & MIC can yield options for individualized treament.

CCGHE at ATS 2017

Post Date: 
2017-05-08
Abstract presentations from the American Thoracic Society International Conference in Washington, DC

Advancing Global TB Research through RePORT

Post Date: 
2016-02-29
Regional Prospective Observational Research for Tuberculosis (RePORT) International is a large, international tuberculosis research effort being undertaken by 4 regional consortia: RePORT Brazil, RePORT South Africa, RePORT Indonesia, and RePORT India. While each region collects and maintains its...